ADCYAP1 and migraine disorder: Thereof, especially agents with high vasoactive potential as CGRP and pituitary adenylate cyclase-activating polypeptide (PACAP) have become the focus in migraine research (Ashina et al., 2017; Ashina et al., 2021a).